A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Phase 1
Completed
- Conditions
- Hyperhidrosis
- Interventions
- Drug: BBI-4000
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT02058264
© Copyright 2025. All Rights Reserved by MedPath